PDCD1 and melanoma: Consequently, the integration of CTLA-4/PD-1 inhibitors with small-molecule agents, antibodies, cellular therapies, and vaccines is emerging as a promising strategy for melanoma brain metastases (MBM) and warrants validation through prospective clinical trials incorporating stratified brain metastasis cohorts or dedicated MBM arms (see Table 4).